Schrödinger, Inc. (Nasdaq: SDGR) is revolutionizing the way drugs and materials are discovered with its physics-based computational platform. On April 14, 2023, the company granted a non-statutory stock option to purchase 2,400 shares of its common stock and restricted stock units (RSU) with respect to 1,800 shares of the company’s common stock to two newly hired employees, as part of their employment compensation. This grant was approved by the compensation committee of the board of directors and was made in accordance with Nasdaq Listing Rule 5635(c)(4).
Schrödinger’s stock option offers its employees the chance to purchase shares at the closing price of $27.49 per share. With a ten-year term, this exciting opportunity begins with 25 percent of the shares vesting after just one year of continuous service and the remainder vesting in equal monthly increments over the next three years. This is an incredible opportunity for employees to invest in their future and benefit from the company’s success.
Our RSUs are designed to incentivize long-term employment, with 25 percent vesting after the employee completes a full year of service and the remaining balance vesting in equal yearly installments over the next three years. This reward structure provides employees with the assurance that their hard work and dedication will be rewarded over the long term.
The 2021 Inducement Equity Incentive Plan offers exciting grants for those eligible! These grants come with terms and conditions of award agreements that must be followed to secure the incentive. It’s a great opportunity that should not be missed!
About Schrödinger
Schrödinger is revolutionizing the way therapeutics and materials are discovered. Through the development of a physics-based computational platform, this cutting-edge technology enables the rapid and cost-effective discovery of high-quality, novel molecules for use in drug development and materials applications.
This platform has been licensed by biopharmaceutical and industrial companies, academic institutions, and government laboratories from all over the world. Additionally, Schrödinger’s highly experienced drug discovery team has been utilizing the software platform to further advance a portfolio of collaborative and proprietary programs in order to address the world’s unmet medical needs.
Schrödinger, a leading innovator in the field of computational chemistry, has been a trailblazer since its founding in 1990. With a global reach of over 70 countries and a passionate team of 800 employees, the company continues to revolutionize the industry with cutting-edge discoveries and groundbreaking collaborations.